RxDoctor Payments DataLook up a doctor →

Michael Snyder, MD

Neurology · Madison, WINPI 1932239142

Payments from drug & device makers

$283,788in general payments, 2019–2025

Across 617 payments — averaging $459.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$249K
  • Pfizer$32K
  • Neurocrine Biosciences, Inc.$195
  • Livanova USA, Inc.$177
  • Johnson & Johnson$176
  • Axsome Therapeutics, Inc.$140
  • plus $1K from 23 others

What the payments were for

  • Consulting fees$2,4401%
  • Speaking & faculty fees$265,26193%
  • Travel & lodging$4,3622%
  • Food & beverage$11,6894%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$283,788 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Wisconsin.

See all neurology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$120,534
Medicare patients
125
Services billed
13,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate29$43,969
UbrelvyUbrogepant29$42,441
Emgality PenGalcanezumab-Gnlm37$28,149
QuliptaAtogepant15$20,350
Aimovig AutoinjectorErenumab-Aooe22$16,283
Pregabalin40$1,517
RizatriptanRizatriptan Benzoate42$1,013
Carbidopa-LevodopaCarbidopa/Levodopa42$952
Gabapentin38$885
Levetiracetam21$811
Lamotrigine14$483
Pramipexole DihydrochloridePramipexole Di-Hcl41$420
Amitriptyline Hcl20$320
Carbidopa-Levodopa ErCarbidopa/Levodopa11$271
Duloxetine Hcl32$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$249,174$62,79044 claims
PfizerNurtec Odt$32,438$43,96929 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Wisconsin.

Other neurology in Madison

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →